Anterogen.Co.,Ltd. Stock price

Equities

A065660

KR7065660003

Pharmaceuticals

End-of-day quote Korea S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
14,430 KRW -2.70% Intraday chart for Anterogen.Co.,Ltd. -1.70% -15.56%
Sales 2022 6.59B 4.88M Sales 2023 6.5B 4.82M Capitalization 166B 123M
Net income 2022 -6.84B -5.07M Net income 2023 -2.84B -2.11M EV / Sales 2022 15.1 x
Net cash position 2022 43.26B 32.05M Net cash position 2023 40.59B 30.08M EV / Sales 2023 19.3 x
P/E ratio 2022
-20.8 x
P/E ratio 2023
-58.5 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 77.46%
More Fundamentals * Assessed data
Dynamic Chart
Anterogen.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment CI
Anterogen.Co.,Ltd. announced that it has received KRW 12 billion in funding CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 12 billion in funding CI
An unknown buyer acquired 3.37% stake in Anterogen.Co.,Ltd. for KRW 10 billion. CI
Anterogen.Co.,Ltd. announced that it has received KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm CI
Anterogen.Co.,Ltd. announced that it has received KRW 13.999979 billion in funding from EM-Tech. CO., LTD. CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 13.999979 billion in funding from EM-Tech. CO., LTD. CI
Anterogen.Co.,Ltd. announced that it has received KRW 6 billion in funding CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 6 billion in funding CI
Anterogen.Co.,Ltd. announced that it has received KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, and another investor CI
Anterogen.Co.,Ltd. announced that it has received KRW 19.99925713 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm CI
More news
1 day-2.70%
1 week-1.70%
Current month+2.92%
1 month+0.56%
3 months-10.37%
6 months+2.63%
Current year-15.56%
More quotes
1 week
14 320.00
Extreme 14320
14 880.00
1 month
13 630.00
Extreme 13630
14 920.00
Current year
13 200.00
Extreme 13200
17 390.00
1 year
12 300.00
Extreme 12300
23 850.00
3 years
12 300.00
Extreme 12300
101 500.00
5 years
12 300.00
Extreme 12300
101 500.00
10 years
12 300.00
Extreme 12300
238 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 04-02-29
Chief Executive Officer 69 00-03-15
Chief Tech/Sci/R&D Officer 48 02-08-31
Members of the board TitleAgeSince
Chief Executive Officer 69 00-03-15
Chief Executive Officer 55 04-02-29
Director/Board Member 70 17-02-28
More insiders
Date Price Change Volume
24-03-27 14,430 -2.70% 13,336
24-03-26 14,830 +0.54% 23,114
24-03-25 14,750 +0.68% 19,805
24-03-22 14,650 +0.07% 7,896
24-03-21 14,640 -0.27% 14,772

End-of-day quote Korea S.E., March 26, 2024

More quotes
ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohn's fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.
More about the company
  1. Stock
  2. Equities
  3. Stock Anterogen.Co.,Ltd. - Korea S.E.